dipyridamole has been researched along with Cryptogenic Fibrosing Alveolitis in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, MX | 1 |
| Chen, YQ | 1 |
| Liu, RD | 1 |
| Huang, Y | 1 |
| Zhang, C | 1 |
1 other study available for dipyridamole and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Discovery of Dipyridamole Analogues with Enhanced Metabolic Stability for the Treatment of Idiopathic Pulmonary Fibrosis.
Topics: Animals; Dipyridamole; Idiopathic Pulmonary Fibrosis; Microsomes, Liver; Molecular Docking Simulatio | 2022 |